The Cannabinoid Evaluation and Recommendation System (CbERS): Development of a Clinical Decision Framework for Medical Cannabis Therapy

Melani Kane, PharmD
International Society of Cannabis Pharmacists (ISCPh)

Background: Medical cannabis therapy often requires iterative modification of dose, cannabinoid ratio, timing, frequency, formulation, or route of administration to optimize therapeutic response and tolerability. However, there is no standardized clinical framework for classifying common therapeutic problems and linking them to targeted treatment modifications.

Objective: To develop a structured clinical decision framework for classifying therapeutic response to medical cannabis and identifying the primary treatment domain requiring modification.

Methods: The Cannabinoid Evaluation and Recommendation System (CbERS) was developed as a clinically derived framework based on recurring therapeutic management patterns observed during pharmacist-led medical cannabis care and further refined during scholarly work examining cannabinoid safety and therapeutic optimization. Common interventions used to address inadequate therapeutic response or treatment-related adverse effects were organized according to three modifiable treatment domains: dose or cannabinoid ratio, timing or frequency, and formulation or route of administration. These domains were incorporated into a bidirectional classification system designed to distinguish inadequate therapeutic response from treatment-related adverse effects and link the identified clinical problem to a targeted therapeutic modification.

Results: Framework development resulted in a seven-point bidirectional classification system ranging from −3 to +3 and a corresponding clinical decision pathway. Negative classifications represent persistent or inadequately controlled target symptoms, positive classifications represent treatment-related adverse effects, and 0 represents adequate symptom control with acceptable tolerability. The absolute value identifies the primary therapeutic intervention domain: dose or cannabinoid ratio (±1), timing or frequency (±2), and formulation or route of administration (±3). The classification therefore identifies both the direction of the therapeutic problem and the treatment domain for modification rather than grading symptom or adverse-effect severity.

Conclusions: CbERS provides a structured approach for translating assessment of therapeutic response and tolerability into targeted modifications of medical cannabis therapy. By standardizing classification around modifiable treatment domains, the framework may support more consistent clinical decision-making and documentation across medical cannabis practice settings. Formal evaluation of the framework’s validity, reliability, clinical utility, and relationship to patient outcomes is warranted.